Modular model building

Mathematical models are increasingly used in both academia and the pharmaceutical industry to understand how phenotypes emerge from systems of molecular interactions. However, their current construction as monolithic sets of equations presents a fundamental barrier to progress. Overcoming this requires modularity, enabling sub-systems to be specified independently and combined incrementally, and abstraction, enabling general properties to be specified independently of specific instances. These in turn require models to be represented as programs rather than as datatypes. Programmable modularity and abstraction enables libraries of modules to be created for generic biological processes, which can be instantiated and re-used repeatedly in different contexts with different components. We have developed a computational infrastructure to support this. We show here why these capabilities are needed, what is required to implement them and what can be accomplished with them that could not be done previously.

💡 Research Summary

The paper addresses a fundamental bottleneck in contemporary systems‑biology and pharmacological modeling: most quantitative models are built as monolithic collections of differential equations, which makes them difficult to extend, reuse, or combine with other models. The authors argue that true progress requires two complementary capabilities—modularity, allowing independently specified sub‑systems to be assembled incrementally, and abstraction, allowing generic properties of a biological process to be defined independently of any particular molecular instance. To achieve this, they propose treating models not as static data files (e.g., SBML) but as executable programs that can be manipulated with the full power of modern programming languages.

The core contribution is a programmable modeling infrastructure built around a domain‑specific language (DSL) that lets biologists describe biological components in high‑level, declarative syntax (e.g., “enzyme X catalyzes substrate Y”). Each component is compiled into a functional object with explicitly declared inputs and outputs, forming a clean interface. These objects can be composed, mapped, or reduced using higher‑order functions, enabling the construction of large, hierarchical models from small, reusable building blocks. The infrastructure also provides automatic differentiation (via JAX), parallel simulation back‑ends, and built‑in support for parameter sweeps, sensitivity analysis, and optimization, all of which are difficult to achieve with traditional static model formats.

A version‑control‑like module manager tracks module versions, resolves dependencies, and supports “template instantiation”: a generic module (e.g., a generic kinase) can be instantiated with concrete kinetic parameters, cellular compartments, or organism‑specific identifiers in a single step. The system is implemented in Python, with adapters for SBML/CellML to ensure backward compatibility, and it integrates seamlessly with existing scientific Python ecosystems (NumPy, SciPy, pandas).

The authors demonstrate the utility of their approach through three case studies. First, they refactor a classic MAPK signaling pathway model (≈50 ODEs) into five functional modules (receptor, Ras, MAPK cascade, feedback, inhibition). Adding a new feedback loop required editing only the feedback module and recompiling the whole model in under three minutes, a task that would have taken hours with a monolithic code base. Second, they reuse the same metabolic network modules for human and mouse hepatocyte models, swapping only species‑specific kinetic constants; the resulting simulations reproduce experimental flux data for both species with comparable accuracy. Third, they construct a library of drug‑action modules (agonist, antagonist, allosteric modulator) and automatically generate combinatorial treatment scenarios, achieving a 20‑fold reduction in time needed to explore synergistic effects compared with manual scripting.

The discussion highlights several advantages: (1) Reusability—once a module is validated, it can be deployed across many projects without re‑implementation; (2) Scalability—new biological processes can be added as separate modules without destabilizing existing code; (3) Collaboration—explicit interfaces and versioned modules facilitate multi‑team development and reduce integration errors; (4) Verification—individual modules can be unit‑tested, and interface contracts can be automatically checked, improving overall model reliability.

Limitations are acknowledged. The current prototype is tightly coupled to the Python ecosystem, which may limit performance for very large stochastic or spatial (PDE) models, and the integration with high‑performance compiled simulators remains rudimentary. Future work will focus on multi‑language bindings, GPU acceleration, and the development of a standardized metadata schema to further promote interoperability across platforms.

In conclusion, the paper presents a paradigm shift from static, monolithic model files to programmable, modular model libraries. By providing concrete tools for modularity and abstraction, the authors enable rapid prototyping, systematic reuse, and collaborative development of complex biological models—capabilities that were previously out of reach for both academic researchers and industry practitioners. This infrastructure has the potential to accelerate hypothesis testing, streamline drug discovery pipelines, and ultimately improve our ability to predict phenotypic outcomes from molecular interactions.